When inking companion diagnostic deals with drug developers, most test makers are trying to get beyond fee-for-service arrangements and strike more creative agreements with potential for bigger profits over a longer period of time.
Quest Diagnostics has published a validation study of its laboratory-developed HIV tropism test that uses a combination of Sanger sequencing and next-generation sequencing on Roche's 454 GS Junior platform.
A Supreme Court decision against drug developers in Sorrell v. IMS Health could potentially hamper how pharmacy benefit managers can use physician prescription data to drive adoption of pharmacogenomically guided products.
Using a systems biology approach, researchers from Switzerland and the US have identified epistatic interactions involving mutations in two HIV-1 enzymes that can help predict the virus' ability to replicate in the presence or absence of more than a dozen drugs.
Although the collaboration is aimed at increasing physician knowledge of genomic testing associated with all HIV drugs, it appears to have stemmed from lower-than-expected sales of Pfizer's CCR5-antagonist Selzentry.